Shares of Avinger, Inc. (AVGR) are surging over 85% on Monday after the company announced the official release of its Tigereye ST image-guided chronic total occlusion (CTO) crossing device.<\/p>\n
AVGR is trading on the Nasdaq at $7.65, up 85.23% or $3.52 per share. It has traded between $4.14 and $24.30 in the past 52-week period.<\/p>\n
Before the official launch, the company had conducted a limited release at 11 clinical centers in the U.S., with approximately 50 CTO procedures performed with Tigereye ST by 13 physicians. It resulted in a successful demonstration of the implementation of the new design features into the platform, safety profile, and efficacy in crossing challenging lesions. <\/p>\n
After using Tigereye ST, Dr. Jaafer Golzar, an interventional cardiologist, Director of Endovascular Intervention at Advocate Christ Medical Center, and Avinger’s Chief Medical Officer, commented, “This device represents one of the most significant advancements in Avinger’s image-guided technologies for the treatment of peripheral artery disease. Tigereye ST incorporates a robust new distal tip design to cross longer and more complex lesions and device features to make image interpretation easier, building on enhanced imaging, higher rotational speeds, and precise user control of the Tigereye platform. The unique combination of onboard image guidance, steerability, ease of use, and crossing power expands the number of patients eligible for minimally invasive revascularization.”<\/p>\n
Tigereye ST features high definition, real-time intravascular imaging, and a user-controlled deflectable tip designed to assist in steerability within the lumen. Additionally, Tigereye ST works well with Avinger’s other image-guided atherectomy devices, including the Pantheris, Pantheris LV, and Pantheris SV. <\/p>\n